['lizbeth]

If you look at page 12 under: Analysis of recurrence prognostic factors and variations in recurrence risk over time

For the HER2-enriched subtype, the first peak occurred at approximately the same time, nearly 20 months for both groups, but the maximum risk was 1.0% (95% CI: 0.5%-2%) in patients with Ki-67 <14% and 1.3% (95% CI: 0.9%-3.1%) in those cases with Ki-67 ≥14%. A second risk peak at 72 months appears for both HER2 populations, but interestingly the magnitude in this case seems to be higher in the HER2-enriched with Ki-67 <14% (0.75%; 95% CI: 0.3%-1.8%) than with Ki-67 ≥14%

Here they state for both Her2 populations there is a peak at 72 months and it was higher for the lower KI67 scores.